CORRESP Filing
Xilio Therapeutics, Inc.
Date: May 6, 2025 · CIK: 0001840233 · Accession: 0001558370-25-006516
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285703
Letter
May 6, 2025 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Alan Campbell Re: Xilio Therapeutics, Inc. Registration Statement on Form S-3 Filed March 11, 2025 File No. 333-285703 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Xilio Therapeutics, Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-285703), so that it may become effective at 9:00 a.m., Eastern Time, on May 8, 2025, or as soon as practicable thereafter. Very truly yours, XILIO THERAPEUTICS, Inc. By: /s/ René Russo Name: René Russo Title: President and Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm May 6, 2025 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Alan Campbell Re: Xilio Therapeutics, Inc. Registration Statement on Form S-3 Filed March 11, 2025 File No. 333-285703 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Xilio Therapeutics, Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-285703), so that it may become effective at 9:00 a.m., Eastern Time, on May 8, 2025, or as soon as practicable thereafter. Very truly yours, XILIO THERAPEUTICS, Inc. By: /s/ René Russo Name: René Russo Title: President and Chief Executive Officer